BPT Crunch

Companies on the Cutting Edge of Healthcare Innovations

back to Marketplace

Lantern Pharma

Lantern Pharma logo

Founded
2013
Patents
15
Clinical Trials
5
Publications
9

Technologies

AI Companies (Drug Discovery)

Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action. Lantern also rescues and revitalizes abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials.

Lantern Pharma recognizes that the high cost and low success rates in oncology drug development largely stem from the inability to appropriately stratify patient populations prior to enrollment, and also from the inability to fully elucidate mechanisms of action that can suggest potent therapy combinations. Our approach, which leverages our RADR™ platform helps to provide rapid, meaningful insight to both of these central problems in oncology.

Lantern is focused on accelerating personalized cancer therapy development through the use of AI and genomic-based patient stratification.

cancer drug development genetic screen precision oncology


Posts Mentioning This Company

How AI Empowers Biomarker-Driven Clinical Trials

  
Clinical trials are the lifeline of modern medicine, bridging the gap between lab-borne scientific discoveries and the availability of life-saving treatments for patients. Unfortunately, the success rate of clinical trials, particularly in the field of oncology, is not as robust as one might hope. In fact, a 2019 study of …

How AI Enables Precision Oncology

  
Lantern Pharma’s AI-driven drug discovery platform RADR® enables value creation across multiple dimensions of the oncology drug development process: from the expansion of therapeutic indications and the identification of drug combinations for use in precision oncology, as well the creation of patient response signatures or biomarker profiles that can be …

9 Notable AI Companies in Clinical Research to Watch in 2023

  
The clinical trial is a critical stage of drug development workflow, with an estimated average success rate of about 11% for drug candidates moving from Phase 1 towards approval. Even if the drug candidate is safe and efficacious, clinical trials might fail due to the lack of financing, insufficient enrollment, …

9 Publicly Traded Biotechs Utilizing AI-based Research Platforms

  
In a report, The Landscape of Artificial Intelligence (AI) In The Pharmaceutical Research, the community of AI-driven drug discovery companies is represented by more than 400 players, focusing on a wide scale of applications from target discovery to clinics. A few companies managed to build sophisticated AI-driven end-to-end drug discovery platforms, …

A Parade of AI-driven Biotechs Going Public in 2020-2021

  
Over 2020-2021 we have seen a remarkable parade of artificial intelligence (AI), focused on discovering novel therapeutics, going public. This reflects a continuing interest in AI as a transformative technology for the pharmaceutical industry and increasing belief in the wave of technology-driven “neo-biotechs”. Here we list some notable companies which …

Artificial Intelligence Yields Early Results in Drug Discovery

  
A historically significant milestone has just been reached by Oxford, UK-based Exscientia, which used its artificial intelligence (AI)-based drug discovery platform Centaur Chemist™ to deliver the first drug candidate in the framework of their multiyear collaboration with GSK. This AI-derived small molecule is a highly potent in vivo active substance …
SHARE Share in Facebook Share in Twitter Share in LinkedIn Send by email